Birth control pills Logest: reviews of women and doctors on forums, price and instructions for use

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

A monophasic combination drug that suppresses the secretion of gonadotropic hormones, inhibits the maturation of follicles and suppresses ovulation. The hormonal substances included in the composition increase the viscosity of the mucus of the vagina and cervical canal and change the endometrium, which prevents the penetration of sperm into the cervical canal, on the one hand, and reduces the likelihood of egg implantation, on the other. Affect the movement of sperm in the fallopian tubes.

Pharmacokinetics

Gestodene is quickly absorbed after administration and after 1 hour its maximum content is noted in the blood. In the blood, it binds to albumin and special globulin (SHBG) by 69%. When taken daily, the content of gestodene in the blood increases 4 times. While taking the second half of the tablets, a state of equilibrium of its level in the blood is noted, the decrease of which occurs in two phases. Gestodene is completely metabolized and is excreted in the form of metabolites in urine and bile (half-life 24 hours).

Ethinyl estradiol is also completely absorbed from the intestine. Its content in serum peaks after 1-2 hours. The decrease in the level of the substance in the blood occurs in two phases. Ethinyl estradiol in the form of metabolites is excreted in bile and urine. Equilibrium concentration is achieved after 5-6 days from the start of taking the drug.

Contraindications

angina pectoris, hypertension, myocardial infarction;
history of cerebrovascular accidents, including transient ones;
presence of risk factors for thrombosis ;
diabetes mellitus complicated by vascular damage;
pancreatitis;
severe liver and kidney diseases;
decreased blood clotting;
hormone-dependent breast tumors ;
suspected pregnancy ;
bleeding from the genital tract of unknown etiology;
epilepsy;
retinal vascular thrombosis;
thrombosis of the veins of the extremities;
overweight;
hypersensitivity to gestodene or ethinyl estradiol.

Side effects of Logest

Low-dose hormonal contraceptives (containing minimal doses of estrogen and progesterone) are less likely to cause adverse reactions than high-dose ones, but you need to be aware of them:

soreness and enlargement of the mammary glands, discharge from them;
spotting and uterine bleeding;
changes in vaginal secretion;
depression , increased fatigue , headache (in the first months of use);
abdominal pain, nausea and vomiting ;
visual impairment;
rash , erythema multiforme and nodosum , itching ;
acne , baldness ;
jaundice;
swelling and weight gain;
development of thrombosis and thromboembolism .

Since the use of hormonal contraceptives causes side effects, they are prescribed only by a doctor after a thorough examination and determination of the “benefit-risk” of their use. After discontinuation of the drug, the menstrual cycle is restored. Pregnancy after discontinuation of Logest occurs within a year.

Logest®

If any of the conditions, diseases or risk factors listed below currently exist, the potential risks and expected benefits of using COCs, including Logest®, should be carefully weighed in each individual case and discussed with the woman before how she decides to start taking the drug. If any of these conditions, diseases or risk factors worsen, intensify or appear for the first time, a woman should consult her doctor to decide whether to stop taking the drug.

— Diseases of the cardiovascular system

The results of epidemiological studies indicate a relationship between the use of COCs and an increased incidence of venous and arterial thrombosis and thromboembolism (such as deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular disorders). These diseases are rare.

Drugs containing levonorgestrel, norgestimate, or norethisterone are less likely to cause VTE. When using other COCs, such as Logest®, the risk of developing VTE is twice as high. The choice to use a COC with a higher risk of developing VTE can only be made after consultation with the patient to ensure that she fully understands the risk of developing VTE associated with the use of Logest®, the effect of the drug on her existing risk factors and that the risk The development of VTE is maximum during the first year of drug use. An increased risk has been reported when COC use is resumed after a break of 4 weeks or more.

The risk of developing VTE is greatest in the first year of taking such drugs. An increased risk is present after initial use of a COC or resumption of use of the same or a different COC (after a dosing interval of 4 weeks or more). Data from a large prospective study involving 3 groups of patients indicate that this increased risk is predominantly present during the first 3 months.

The overall risk of VTE in patients taking low-dose COCs (containing less than 0.05 mg ethinyl estradiol) is two to three times higher than in non-pregnant patients not taking COCs, however, this risk remains lower than the risk of VTE with pregnancy and childbirth.

VTE can be life-threatening or lead to death (in 1-2% of cases).

VTE, manifested as deep vein thrombosis and/or pulmonary embolism, can occur with the use of any COC.

It is extremely rare when using COCs that thrombosis of other blood vessels occurs, for example, hepatic, mesenteric, renal, cerebral veins and arteries or retinal vessels.

Symptoms of deep vein thrombosis (DVT): unilateral swelling of the lower extremity or along the vein in the lower extremity, pain or discomfort in the lower extremity only in an upright position or when walking, local increase in temperature, redness or discoloration of the skin in the affected lower extremity.

Symptoms of pulmonary embolism (PE): difficulty or rapid breathing; sudden cough, including with hemoptysis; sharp pain in the chest, which may intensify with deep inspiration; sense of anxiety; severe dizziness; fast or irregular heartbeat. Some of these symptoms (eg, shortness of breath, cough) are nonspecific and may be misinterpreted as signs of other more common and less severe complications (eg, respiratory tract infection).

Arterial thromboembolism can lead to stroke, vascular occlusion, or myocardial infarction. Symptoms of a stroke: sudden weakness or loss of sensation in the face, limbs, especially on one side of the body, sudden confusion, problems with speech and understanding; sudden unilateral or bilateral vision loss; sudden disturbance in gait, dizziness, loss of balance or coordination; sudden severe or prolonged headache for no apparent reason; loss of consciousness or fainting with or without convulsions. Other signs of vascular occlusion: sudden pain, swelling and slight cyanosis of the extremities, “acute” abdomen.

Symptoms of myocardial infarction: pain, discomfort, pressure, heaviness, a feeling of compression or fullness in the chest or behind the sternum, radiating to the back, jaw, upper limb, epigastric region; cold sweat, nausea, vomiting or dizziness, severe weakness, anxiety or shortness of breath; fast or irregular heartbeat. Arterial thromboembolism can be life-threatening or lead to death.

In women with a combination of several risk factors or high severity of one of them, the possibility of their mutual reinforcement should be considered. In such cases, the degree of increase in risk may be higher than with a simple summation of factors. In this case, taking Logest® is contraindicated (see section “Contraindications”).

The risk of developing thrombosis (venous and/or arterial) and thromboembolism or cerebrovascular disorders increases:

- with age;

- in smokers (with an increase in the number of cigarettes or an increase in age, the risk increases, especially in women over 35 years old);

- in the presence of a family history (for example, venous or arterial thromboembolism ever in close relatives or parents under the age of 50 years). In the case of a hereditary or acquired predisposition, the woman should be examined by an appropriate specialist to decide on the possibility of taking COCs;

— for obesity (body mass index 30 kg/m2 or more);

- with dislipoproteinemia;

- for arterial hypertension;

- for migraine;

- for diseases of the heart valves;

- with atrial fibrillation;

- in case of prolonged immobilization, major surgery, any operation on the lower extremities or major trauma. In these cases, the use of COCs should be stopped (in the case of planned surgery, at least four weeks before it) and not resumed for two weeks after the end of immobilization. Temporary immobilization (eg, air travel lasting more than 4 hours) may also be a risk factor for the development of VTE, especially in the presence of other risk factors.

The possible role of varicose veins and superficial thrombophlebitis in the development of VTE remains controversial.

The increased risk of thromboembolism in the postpartum period should be taken into account.

Peripheral circulatory disorders may also occur in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell anemia.

An increase in the frequency and severity of migraine (which may precede cerebrovascular events) during the use of COCs may be grounds for immediate discontinuation of these drugs.

Biochemical indicators indicating a hereditary or acquired predisposition to the development of venous or arterial thrombosis include: resistance to activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).

When assessing the risk-benefit ratio, it should be taken into account that adequate treatment of the relevant condition may reduce the associated risk of thrombosis. It should also be taken into account that the risk of thrombosis and thromboembolism during pregnancy is higher than when taking low-dose COCs (containing less than 0.05 mg ethinyl estradiol).

— Tumors

The most significant risk factor for developing cervical cancer is persistent human papillomavirus infection. There are reports of a slight increase in the risk of developing cervical cancer with long-term use of COCs. However, the connection with taking COCs has not been proven. Controversy remains regarding the extent to which these findings are related to screening for cervical pathology or to sexual behavior (lower use of barrier methods of contraception).

A meta-analysis of 54 epidemiological studies showed that there is a slightly increased relative risk of developing breast cancer diagnosed in women currently taking COCs (relative risk 1.24). The increased risk gradually disappears within 10 years of stopping these drugs. Because breast cancer is rare in women under 40 years of age, the increase in the incidence of breast cancer in women who are currently or recently taking COCs is small relative to the overall risk of breast cancer. Its connection with COC use has not been proven. The observed increased risk may also be a consequence of earlier diagnosis of breast cancer in women using COCs (they are diagnosed with earlier clinical forms of breast cancer than women not taking COCs), the biological effects of COCs, or a combination of both.

In rare cases, during the use of COCs, the development of benign, and in extremely rare cases, malignant liver tumors, which in some cases led to life-threatening intra-abdominal bleeding, was observed. In case of severe abdominal pain, liver enlargement or signs of intra-abdominal bleeding, this should be taken into account when making a differential diagnosis.

— Other states

In women with hypertriglyceridemia (or a family history of this condition), the risk of developing pancreatitis may increase while taking COCs.

Although slight increases in blood pressure have been described in many women taking COCs, clinically significant increases have rarely been reported. However, if a persistent clinically significant increase in blood pressure develops while taking COCs, these drugs should be discontinued and treatment of arterial hypertension should be initiated. COCs can be continued if normal blood pressure levels are achieved with antihypertensive therapy.

The following conditions have been reported to develop or worsen both during pregnancy and while taking COCs, but their relationship with COC use has not been proven: cholestatic jaundice and/or pruritus associated with cholestasis; formation of gallstones; porphyria; systemic lupus erythematosus; hemolytic-uremic syndrome; chorea; herpes during pregnancy; hearing loss associated with otosclerosis. Cases of Crohn's disease, ulcerative colitis, worsening of endogenous depression and epilepsy during the use of COCs have also been described.

In women with hereditary forms of angioedema, exogenous estrogens may cause or worsen symptoms of angioedema.

Acute or chronic liver dysfunction may require discontinuation of COCs until liver function tests return to normal. Recurrence of cholestatic jaundice, which developed for the first time during a previous pregnancy or previous use of sex hormones, requires discontinuation of COC use.

Although COCs may have an effect on insulin resistance and glucose tolerance, there is generally no need for dose adjustment of hypoglycemic agents in diabetic patients using low-dose COCs (containing less than 0.05 mg ethinyl estradiol). However, women with diabetes mellitus should be carefully monitored while taking COCs.

Chloasma can sometimes develop, especially in women with a history of pregnancy chloasma. Women with a tendency to chloasma should avoid prolonged exposure to the sun and exposure to ultraviolet radiation while taking COCs.

Laboratory tests

The use of drugs such as Logest® may affect the results of some laboratory tests, including biochemical indicators of liver, thyroid, kidney and adrenal function, the concentration of transport proteins in plasma (for example, corticosteroid binding globulin, lipid/lipoprotein fractions, parameters of carbohydrate metabolism, coagulation and fibrinolysis). These changes usually remain within normal physiological values.

Reduced efficiency

The effectiveness of COCs may be reduced in the following cases: missed pills, gastrointestinal disorders or as a result of drug interactions.

Effect on bleeding pattern

While taking COCs, irregular bleeding may occur (“spotting” and/or “breakthrough” bleeding), especially during the first months of use. Therefore, any irregular bleeding should be assessed only after an adaptation period of at least 3 cycles of the drug.

If irregular bleeding recurs or develops after previous regular cycles, careful evaluation should be performed to rule out malignancy or pregnancy.

Some women may not develop bleeding during a break in taking pills; “ooContraindications” and “Use with caution”;

— Local compaction in the mammary gland;

- Concomitant use of other medications (see also “Interaction with other medications”);

- If prolonged immobilization is expected (for example, a cast is applied to the lower limb), hospitalization or surgery is planned (at least four weeks before the proposed operation);

- Unusually heavy bleeding from the vagina;

- Missed a pill in the first week of taking the drug and had sexual intercourse seven days or less before;

— Absence of regular menstrual-like bleeding two times in a row or suspicion of pregnancy (you should not start taking pills from the next package before consulting your doctor).

You should stop taking the tablets and consult your doctor immediately if there are possible signs of thrombosis, myocardial infarction or stroke: unusual cough: unusually severe pain in the chest, radiating to the left arm; unexpected shortness of breath, unusual, severe and prolonged headache or migraine attack; partial or complete loss of vision or double vision; slurred speech; sudden changes in hearing, smell, or taste; dizziness or fainting; weakness or loss of sensation in any part of the body; severe abdominal pain; severe pain in the lower limb or sudden swelling of any of the lower limbs.

Contraceptive pills Logest, instructions for use (Method and dosage)

The tablets are taken orally every day, in the order indicated on the package, preferably at the same time, without a break for 21 days. Then there is a break of 7 days, during which bleeding appears, after which they move on to taking new tablets.

If the woman has not previously taken hormonal contraceptives

Reception begins on the first day of the menstrual cycle. If you start taking it on the 2nd - 4th day of the cycle, then it is necessary to use barrier contraception for the first week of taking the pills.

Switching from other combined contraceptives

It is necessary to immediately start taking this contraceptive after taking the active tablet of the previous hormonal contraceptive.

When switching from intrauterine hormonal contraception containing progestogen, intradermal implants and injections, mini-pills

This drug is taken any day after finishing the mini-pill. When using injections or implants, the first tablet is taken on the day the intradermal implant is removed or the contraceptive injection ends. However, in all cases, barrier contraception is prescribed for a week.

How to take the drug after an early abortion

The drug is started immediately. In this case, there is no need for additional contraception.

Birth control pills after childbirth or late pregnancy abortion

Taken 21-28 days after physiological birth (or induced abortion performed in the second trimester). In case of a later start, a barrier method of contraception is used for a week.

If you miss taking a pill, there are separate instructions for using Logest.

Logest

Low-dose monophasic combined oral contraceptive based on estrogen (ethinyl estradiol) and progestogen (gestodene). The contraceptive effect is achieved by suppressing ovulation, changing the properties of cervical mucus and changing the endometrium. Sperm cannot penetrate the uterus, and the fertilized egg cannot attach to the surface of the endometrium.

In addition to protecting against unwanted pregnancy, Logest has a beneficial effect on the female body: the menstrual cycle becomes more regular, the pain and intensity of menstruation decreases, and the risk of iron deficiency anemia decreases.

Contraindications to taking Logest may include:

thrombosis and thromboembolism;
myocardial infarction, angina pectoris;
migraine;
diabetes mellitus with vascular complications;
damage to the valvular apparatus of the heart, heart rhythm disturbances, diseases of the cerebral vessels or coronary arteries of the heart;
high blood pressure;
pancreatitis with severe hypertriglyceridemia currently or in history;
liver failure and severe liver diseases, liver tumors;
hormone-dependent malignant diseases (including genital organs or mammary glands) or suspicion of them;
vaginal bleeding of unknown origin;
prolonged immobility, serious injuries and surgical interventions.

Logest should not be taken during pregnancy and lactation. If pregnancy occurs while taking the drug, it should be stopped immediately. There is no need to fear for possible pathologies of the fetus, since extensive clinical studies prove that taking hormonal contraceptives in the early stages of pregnancy does not have a significant negative effect on the fetus.

With extreme caution and with constant monitoring, Logest can be prescribed in the following cases:

obesity;
thrombophlebitis;
otosclerosis with hearing loss;
idiopathic jaundice or itching during previous pregnancy;
migraine;
congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes);
diabetes;
sickle cell anemia;
arterial hypertension.

Directions for use and doses

Logest is taken as one tablet per day, preferably at the same time. The period of continuous use is 21 days, until all the tablets from the package are consumed. This is followed by a week-long break, during which menstrual-like bleeding usually occurs.

Start of reception

If you have not taken any hormonal contraceptives in the previous month, then the first Logest tablet is taken on the first day of the menstrual cycle, that is, on the first day of menstrual bleeding. It is possible to postpone the start of use to days 2-5 of the menstrual cycle, but in this case, barrier methods of contraception should be additionally used for a week.

If you are switching from another combined oral contraceptive, then the first Logest tablet is taken the next day after taking the last active tablet of the previous drug. It is possible to take the usual one-week break between drugs from different packages - if the package of the previous drug contains 21 tablets. If it contains 28 tablets, then the first Logest tablet is taken the next day after taking the last inactive tablet.

If you are making a transition from oral contraceptives containing only gestagens (mini-pills), then the first Logest tablet can be taken any day, without any break.

If you are making a transition from injection methods of contraception, then the first Logest tablet is taken on the day when the next injection would have been given.

If you are switching from an intrauterine contraceptive (for example, Mirena), then the first Logest tablet is taken on the day of its removal.

In all three cases of transition from gestagen-containing contraceptives (mini-pills, injections, intrauterine contraceptives) additional protective measures must be used within a week.

Starting after an abortion or childbirth

If the abortion occurred in the first trimester of pregnancy, then you can start taking Logest immediately. Additional contraceptive protection is not required.

If abortion or childbirth occurred in the second trimester of pregnancy, then taking Logest should be started 21-28 days after childbirth or abortion in the second trimester of pregnancy. If use is started later, it is necessary to use an additional barrier method of contraception during the first 7 days of taking the pill. However, if a woman has already been sexually active, pregnancy should be excluded before taking Logest or she must wait until her first menstruation.

If you forget to take your pill

If the delay is less than 12 hours, the contraceptive effect is not reduced. The drug still has its effects on the body. Therefore, in such a situation, you need to take the pill as soon as possible. No other measures are required. The subsequent tablet is taken according to the usual schedule.

If the delay is more than 12 hours, the contraceptive effect is reduced and conception becomes more likely. Actions in such a situation depend on which week of admission it occurred. You also need to always remember two rules:

Reception of Logest should not be interrupted for a period exceeding seven days.
In order for the maximum contraceptive effect to be achieved, it is necessary to take the drug for at least seven days.

Actions when the interval between two tablets exceeds 36 hours (delay in taking more than 12 hours):

First week of taking the drug

You need to take the missed pill as soon as possible - if the delay is approaching 24 hours, then you need to take two pills at the same time. Then the intake continues according to the usual schedule, but barrier methods of protection are also used during the week. It is necessary to take into account that if there was a sexual contract during the week before missing the pill, there is a possibility of pregnancy. Remember: the more pills you miss, and the closer they are to the week break, the greater the chance of pregnancy. In other words, a missed pill in the third week of use entails a greater likelihood of pregnancy than a missed pill in the first week.

Second week of taking the drug

Take the missed pill as soon as possible, then proceed according to your usual schedule. If a woman is confident that she adhered to her dosage schedule during the week before missing the pill, no additional precautions are required. If the previous appointment occurred with serious deviations from the schedule, then it makes sense to additionally use barrier methods.

Third week of taking the drug

If you miss taking a pill in the third week, the risk of a decrease in the contraceptive effect, as well as the risk of possible pregnancy, is inevitable. You can act in such a situation according to two schemes.

First scheme

Take the missed pill as soon as possible, then take the drug according to your usual schedule.
When all the pills from the current package are drunk, the next package is moved on - that is, without a seven-day break.

With this regimen, the onset of menstrual-like bleeding in the current cycle is unlikely; scanty spotting and breakthrough bleeding may occur while taking the second package.

Second scheme

We consider the current packaging to be complete. We don’t take the remaining pills in it - we take a week’s break, the first day of which is considered the day you missed taking a pill.
After the break, we begin taking tablets from the next package.

If bleeding occurs during the break, pregnancy must be ruled out.

Cases where vomiting or diarrhea occurs within 4 hours after taking a pill should be regarded as missing a pill. And act according to the recommendations presented above.

Possible side effects when taking Logest may be:

soreness and tension of the mammary glands, enlargement of the mammary glands, discharge from the mammary glands;
discharge and breakthrough uterine bleeding;
headache, migraine;
change in libido;
emotional instability;
poor tolerance to contact lenses, blurred vision;
nausea, vomiting, abdominal pain;
skin rash, itching, chloasma;
erythema nodosum, erythema multiforme;
cholestatic jaundice;
swelling;
change in body weight;
allergic reactions;
thrombosis, thromboembolism.

Please note: a number of medications may reduce the contraceptive effect of Logest. These are primarily: phenytoin, barbiturates, primidone, carbamazepine and rifampicin, oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin, ampicillin, tetracycline and preparations containing St. John's wort.

Please also pay attention to some points that are important to understand when taking Logest.

In case of planned surgery, you need to stop taking the drug four weeks in advance, and it is recommended to resume taking it no earlier than two weeks after the end of the immobilization period.
If you have been prescribed medications that affect microsomal enzymes, then during the course of treatment, as well as within 28 days after its completion, a decrease in the contraceptive effect of Logest is noted. In this regard, it is recommended to additionally use barrier methods of contraception. At the same time, if you have taken all the tablets from the package, and 28 days have not yet passed, you need to move on to the next package of Logest without a week's break.
You should consult a doctor in cases where you experience:
severe chest pain
sudden shortness of breath,
causeless cough,
any unusual, severe, long-lasting headache;
problems with vision or speech;
dizziness, loss of consciousness;
weakness;
"acute belly"
Women suffering from diabetes, high blood pressure, and recurrent headaches should be especially carefully observed by a doctor.
Preventive examinations by a gynecologist should be performed every six months.
Logest is not recommended for smoking women over 35 years of age, as it may increase the risk of developing complications of the cardiovascular system.

Taking the drug should be stopped if, while taking:

there is an increase in the frequency and intensity of headaches and migraines;
epileptic seizures occur;
signs of depression increase;
surgical intervention is pending (appointment is stopped 4 weeks before the planned operation and can be resumed 1 week after the patient is mobilized).

Please note: intermenstrual bleeding may occur in the first three months of taking Logest. If they occur after regular cycles have formed, pregnancy and malignant neoplasms should be excluded.

If menstrual-like bleeding does not occur during the period without taking pills (the week between two packs) and the dosage regimen was violated in the previous cycle, it is necessary to take a pregnancy test.

Interaction

There is a decrease in contraceptive protection when taking ampicillins and tetracyclines , since they reduce the circulation of estrogen in the liver, lowering the concentration of ethinyl estradiol.

Sulfonamides, butadione, analgin, amidopyrine enhance the metabolism of steroid hormones included in Logest.

Medicines: barbiturates, carbamazepine, ritonavir, rifampicin, oxcarbazepine, griseofulvin reduce the contraceptive effectiveness of Logest.

Combined contraceptives affect the metabolism of cyclosporine , leading to a decrease in its plasma concentration. Taking estrogen-progestin drugs requires adjustment of the dosage of glucose-lowering drugs, as well as indirect anticoagulants.

Interactions of the drug Logest

Interactions between oral contraceptives and other drugs may result in breakthrough bleeding and/or decreased contraceptive effectiveness. The following interactions have been reported in the literature. Hepatic metabolism: possible interaction with drugs that induce microsomal enzymes, which can cause an increase in the clearance of sex hormones (for example, phenytoin, barbiturates, primidone, carbamazepine, rifampicin and possibly also oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin and drugs containing St. John's wort). Interaction with the enterohepatic circulation: Some clinical studies suggest that the enterohepatic circulation of estrogens may be decreased by certain antibiotics that reduce ethinyl estradiol concentrations (such as penicillin and tetracycline antibiotics). When treating any of the above drugs, a woman should temporarily use a barrier method in addition to taking COCs or choose another method of contraception. When treating with drugs that induce microsomal enzymes, the barrier method must be used throughout the entire period of treatment with the corresponding drug and for another 28 days after stopping its use. When treating with an antibiotic (with the exception of rifampicin and griseofulvin), the barrier method should be used for another 7 days after discontinuation of the antibiotic. If the barrier method is still being used, and the tablets in the PDA package have already run out, taking the tablets from the next package should be started without the usual break. Oral contraceptives may affect the metabolism of other drugs. Taking this into account, the concentrations of active substances in blood plasma and tissues (for example, cyclosporine) may change. Note. To determine the potential for interaction with drugs that are prescribed concomitantly with COCs, it is recommended that you read the instructions for medical use of these drugs. Impact on laboratory test results Taking contraceptives may affect the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and kidney function, plasma levels of proteins (carriers), such as sex hormone-binding globulin and fractions lipids/lipoproteins, parameters of carbohydrate metabolism, as well as parameters of coagulation and fibrinolysis.

Logest's analogs

Level 4 ATC code matches:
Ovidon

Rigevidon

Non-Ovlon

Mercilon

Yarina Plus

Yarina

Miniziston 20 fem

Novinet

Microgynon

Janine

Lindineth

Cyclo-Proginova

Regulon

Midiana

Belara

Femoden

Jess Plus

Jess

Zoely

Artisia, Lindinet 20, Lindinet 30, Femoden.

Analogues Artisia and Lindinet 20 have the same composition. The preparations Lindinet 30 and Femoden contain gestodene 75 mcg, ethinyl estradiol 30 mcg.

Reviews about Logest

Reviews from women about Logest indicate that the use of the drug is highly reliable. Tolerability of the drug is assessed as very good. Women note that taking the drug does not affect body weight even with long-term use. There is also no androgenic effect on skin and hair growth.

Reviews from doctors indicate the positive clinical characteristics of the drug. Reducing the dose of hormones significantly reduces the number of side effects. At the same time, the drug has high bioavailability , which makes it possible to predict its level in the blood and use it at a lower dose. There is a lower risk of intermenstrual bleeding when taking products containing gestodene. Doctors prescribe it to regulate the menstrual cycle. The drug is effective for heavy, prolonged and painful menstruation. With its use, painful periods are observed less frequently, the intensity of discharge decreases, and the risk of anemia decreases.

Analyzing reviews of Logest on forums, we can conclude that Logest is recommended for women who are starting to “get acquainted” with oral contraceptives. It is used when high-dose drugs are poorly tolerated. In addition, it is used for the treatment and prevention of many gynecological diseases.

Among the disadvantages of the drug, it is noted that it cannot be taken with many medications (even with analgin), the appearance of cellulite . For many, an important point is the price. The high price of this drug is considered a disadvantage.

Logest, 75 mcg+20 mcg, film-coated tablets, 21 pcs.

In case of planned surgery, it is recommended to stop taking the drug at least 4 weeks before the operation and not to resume taking it for 2 weeks after the end of immobilization.

While taking medications that affect microsomal enzymes, and for 28 days after their discontinuation, you should additionally use a barrier method of contraception.

While taking antibiotics such as ampicillins and tetracyclines and for 7 days after their discontinuation, you should additionally use a barrier method of contraception.

If the period of use of the barrier method of protection ends later than the tablet in the package, you need to move on to the next package of Logest® without the usual break in taking the tablet.

If any of the conditions/risk factors listed below currently exist, the potential risks and expected benefits of Logest® treatment should be carefully weighed in each individual case and discussed with the woman before she decides to start taking the drug. If any of these conditions or risk factors worsen, intensify, or appear for the first time, a woman should consult her doctor, who may decide whether to discontinue the drug.

Diseases of the cardiovascular system

There is evidence of an increased incidence of venous and arterial thrombosis and thromboembolism when taking combined oral contraceptives.

However, the incidence of venous thromboembolism occurring with combined oral contraceptives is less than that associated with pregnancy (6 per 10,000 pregnant women per year).

In women taking combined oral contraceptives, extremely rare cases of thrombosis of other blood vessels, such as the hepatic, mesenteric, renal arteries and veins, the central retinal vein and its branches, have been described. The connection with the use of combined oral contraceptives has not been proven.

A woman should stop taking the drug and consult a doctor if symptoms of venous or arterial thrombosis or cerebrovascular disorders develop, which may include: unilateral leg pain and/or swelling; sudden severe chest pain with or without radiating to the left arm; sudden shortness of breath; sudden attack of cough; any unusual, severe, prolonged headache; sudden partial or complete loss of vision; diplopia; slurred speech or aphasia; dizziness; loss of consciousness with/or without a seizure; weakness or very significant loss of sensation that suddenly appears on one side or in one part of the body; movement disorders; symptoms of "acute abdomen".

The risk of thrombosis (venous and/or arterial) and thromboembolism increases: - with age; - in smokers (with an increase in the number of cigarettes or an increase in age, the risk further increases, especially in women over 35 years of age); in the presence of: - family history (i.e. venous or arterial thromboembolism ever in close relatives or parents at a relatively young age); in case of hereditary predisposition, the woman should be examined by an appropriate specialist to decide on the possibility of taking combined oral contraceptives; — obesity (body mass index more than 30 kg/m2); - dislipoproteinemia; - arterial hypertension; - migraine; — diseases of the heart valves; - atrial fibrillation; - prolonged immobilization, major surgery, any leg surgery or major trauma.

In these situations, it is advisable to stop using combined oral contraceptives (in the case of planned surgery, at least 4 weeks before it) and not to resume use for 2 weeks after the end of immobilization.

The increased risk of thromboembolism in the postpartum period should be taken into account.

Circulatory abnormalities may also occur in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell anemia.

An increase in the frequency and severity of migraines during the use of combined oral contraceptives (which may precede cerebrovascular events) may be grounds for immediate discontinuation of these drugs.

Biochemical parameters that may be indicative of hereditary or acquired susceptibility to venous or arterial thrombosis include activated protein C resistance, hyperhomocysteinemia, antithrombin-III deficiency, protein C deficiency, protein S deficiency, the presence of antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) .

Tumors

There are reports of an increased risk of developing cervical cancer with persistent human papillomavirus infection. Its connection with the use of combined oral contraceptives has not been proven. Controversy remains regarding the extent to which these findings relate to sexual behavior and barrier contraceptive use.

It was also found that there is a slightly increased relative risk of developing breast cancer diagnosed in women who used combined oral contraceptives. Its connection with the use of combined oral contraceptives has not been proven. The observed increased risk may be a consequence of earlier diagnosis of breast cancer in women using combined oral contraceptives.

In rare cases, the development of liver tumors has been observed during the use of combined oral contraceptives. The appearance of severe pain in the abdomen or signs of intra-abdominal bleeding, liver enlargement should be taken into account when making a differential diagnosis.

Other states

Women with hypertriglyceridemia (or a family history of this condition) may have an increased risk of developing pancreatitis while taking combined oral contraceptives.

Although slight increases in blood pressure have been described in many women taking combined oral contraceptives, clinically significant increases have rarely been reported. However, if a persistent, clinically significant increase in blood pressure develops while taking combined oral contraceptives, these drugs should be discontinued and treatment of arterial hypertension should be initiated. Taking combined oral contraceptives can be continued if normal blood pressure values are achieved with antihypertensive therapy.

The following conditions have been reported to develop or worsen both during pregnancy and while taking combined oral contraceptives, but their relationship with taking combined oral contraceptives has not been proven: jaundice and/or pruritus associated with cholestasis; formation of gallstones; porphyria; systemic lupus erythematosus; hemolytic uremic syndrome; chorea; herpes during pregnancy; hearing loss associated with otosclerosis. Cases of Crohn's disease and ulcerative colitis have also been described during the use of combined oral contraceptives.

Acute or chronic liver dysfunction may require discontinuation of combined oral contraceptives until liver function tests return to normal. Recurrent cholestatic jaundice, which develops for the first time during pregnancy or previous use of sex hormones, requires discontinuation of combined oral contraceptives.

Although combined oral contraceptives may have an effect on insulin resistance and glucose tolerance, there is no need to change the therapeutic regimen in diabetic patients using low-dose combined oral contraceptives (<0.05 mg ethinyl estradiol). However, women with diabetes mellitus should be carefully monitored while taking combined oral contraceptives.

Women prone to chloasma should avoid prolonged exposure to the sun and ultraviolet radiation while taking combined oral contraceptives.

Laboratory tests

Taking combined oral contraceptives may affect the results of some laboratory tests, including liver, kidney, thyroid, adrenal function, plasma transport protein levels, carbohydrate metabolism, coagulation and fibrinolysis parameters. Changes usually do not go beyond normal values.

Effect on the menstrual cycle

While taking combined oral contraceptives, irregular bleeding (spotting or breakthrough bleeding) may occur, especially during the first months of use. Therefore, any irregular bleeding should be assessed only after an adaptation period of approximately 3 cycles.

If irregular bleeding recurs or develops after previous regular cycles, careful evaluation should be performed to rule out malignancy or pregnancy.

Some women may not develop withdrawal bleeding during a break from taking the tablets. If combined oral contraceptives are taken as directed, the woman is unlikely to be pregnant. However, if combined oral contraceptives have not been taken regularly before, or if there are no 2 withdrawal bleedings in a row, pregnancy should be excluded before continuing to take the drug.

Medical examinations

Before starting to use the drug Logest®, a woman is recommended to undergo a thorough general medical and gynecological examination (including examination of the mammary glands and cytological examination of cervical mucus) and exclude pregnancy. In addition, disorders of the blood coagulation system should be excluded.

In case of long-term use, it is necessary to carry out control examinations, the frequency of which depends on the individual characteristics of the woman.

The woman should be warned that drugs such as Logest® do not protect against HIV infection (AIDS) and other sexually transmitted diseases!

There was no effect on the ability to drive a car or use machinery.

Logest price, where to buy

You can buy it in pharmacies in Moscow and other cities of Russia. For Logest contraceptive pills, the price ranges from 545 rubles. up to 712 rub. for 21 tablets

Online pharmacies in RussiaRussia
Online pharmacies in UkraineUkraine
Online pharmacies in KazakhstanKazakhstan

ZdravCity

Logest dragee 63 pcs. Bayer Weimar GmbH and Co. KG/Bayer AG
1962 rub. order
Logest tablets 21 pcs. Bayer Weimar GmbH and Co.KG
RUR 786 order

Pharmacy Dialogue

Logest (table no. 21) Bayer
RUR 791 order
Logest (tablet. no. 21x3) Bayer
RUB 1,955 order

Pharmacy24

Logest No. 21 tablets Delpharm Lille S.A.S., France
200 UAH.order

PaniPharmacy

Logest tablets Logest etc. No. 21 France, Delpharm Lille
221 UAH order